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Retrospective Matched-Cohort Analysis of Acute Pancreatitis
Induced by 5-Aminosalicylic Acid–Derived Drugs
Ágnes Meczker, MSc,* Alexandra Mikó, MD, PhD,* Noémi Gede, MSc,* Andrea Szentesi, PhD,*†
Andrea Párniczky, MD, PhD,*‡ Szilárd Gódi, MD,§ and Péter Hegyi, MD, PhD, DSc, MAE(Med),||¶#**
on behalf of Hungarian Pancreatic Study Group
Objectives: This study aimed to compare the clinical course of
5-aminosalicylic acid–derived, drug-induced acute pancreatitis (5-ASA–
DIAP) to acute pancreatitis (AP) caused by other etiologies.
Methods: A cohort of patients with 5-ASA–DIAP was established
through literature search. As a control AP (CAP) group, a cohort was generated
froma registry.Data on the diagnostic procedure, symptoms, enzyme elevation,
imaging, severity, and recovery parameters were collected. Causality was
assessed using the Naranjo algorithm.
Results: Twenty-nine articles were included, which describe 36 patients
with fifty-one 5-ASA–DIAP episodes (60.78% female, 39.22% male).
There were 88.2% mild, 3.92% moderate, and 7.84% severe cases of AP
in the 5-ASA–DIAP group, and 70.6%, 25.5%, and 3.92% such cases in
the CAP population, respectively. Symptoms improved significantly faster
(mean ± SE, 2.5 ± 0.34 vs 3.74 ± 0.42 days; P = 0.018); however, pancreatic
enzyme levels normalized significantly more slowly (6.27 ± 1.53 vs
3.63 ± 0.61 days, P = 0.008) in the 5-ASA–DIAP cohort compared with
the CAP group. This study confirms that there are no diagnostic differences
between 5-ASA–DIAP and AP of other etiologies.
Conclusions: Fewer moderate but more severe cases were found in the
5-ASA–DIAP group; therefore, 5-ASA–DIAP must be taken as seriously
as AP of other etiologies.
Key Words: acute pancreatitis, 5-ASA, mesalazine, rechallenge,
drug-induced, IBD
(Pancreas 2019;48: 488–495)
A cute pancreatitis (AP) is a serious disease with high mortality.The reported incidence is variable in different countries
(10–100/100,000 people), and AP is a leading cause of acute hos-
pitalization for gastrointestinal disorders.1 The most common eti-
ologies for AP are gallstones, biliary sludge or microlithiasis,
alcohol, hypertriglyceridemia, post–endoscopic retrograde cholan-
giopancreatography status, hypercalcemia, genetic mutations, infec-
tions or toxins, trauma, anatomic malformation of the pancreas, and
vascular disease.2–4 The rest of the episodes are usually termed
idiopathic. Drug-induced AP (DIAP) is a rare entity, accounting
for approximately 2% to 5% of AP episodes worldwide.5–7 How-
ever, estimates vary because of the challenging diagnosis and the
difficulties of causality assessment. Because it is considered un-
ethical to intentionally rechallenge with the offending drug owing
to the potentially life-threatening nature of AP, DIAP remains a
speculative diagnosis made by exclusion in most cases.
5-Aminosalicylic acid (5-ASA; mesalazine or mesalamine)–
derived drugs are aminosalicylate anti-inflammatory medications
generally considered as safe and effective therapy for patients with
inflammatory bowel disease (IBD). Pancreatitis as an adverse re-
action to 5-ASA–derived drugs was first reported in 1970 by
Block et al8 and was followed by several others.9–11 According
to the literature, DIAP is usually considered self-limited and mild
in clinical course, with easy management, an excellent prognosis,
and low mortality.6 Rapid symptomatic improvement usually oc-
curs after discontinuation of the offending medication.12,13 How-
ever, there are huge variations in clinical course in cases of
5-ASA–induced AP. Our main aims were to investigate whether
5-ASA–DIAP has the characteristics noted previously and to
compare its clinical course with that of AP caused by other, more
common etiologies.
MATERIALS AND METHODS
Systematic Search
Initially, our aimwas to find all reported 5-ASA–DIAP cases
with a systematic search.We searched literature data for retrospec-
tive cohort analyses describing these cases in individual medical
centers. We performed a systematic literature search according
to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guideline. We applied the following PICO format:
P, patients with AP; I, 5-ASA–DIAP; C, AP caused by other etiol-
ogies; and O, severity, mortality, length of hospitalization, imaging
alterations, symptoms, and resolution characteristics of AP. The
search was performed in April 2017 on PubMed, Embase, and
Cochrane Library with the search terms “5-ASAANDpancreatitis”
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and limited to English language and human target (if applicable) re-
gardless of the date of publication. We did not want to limit the
search on cohort analyses; thus, case reports, case series, and other
types of publications were included as well if they contained data
appropriate to our questions. At this point of the work, we realized
that no cohort analysis had been performed on this topic because of
the small study sizes; only individual case reports and case series
were found. The detailed result of the search process is presented
in Figure 1. A retrospective cohort was established of the cases de-
scribed. We identified 36 studies reporting 5-ASA–DIAP.8–10,12–43
In the analysis, we only included studies in which the authors had
concluded that 5-ASA–derived medication is the most probable
cause of the adverse drug reaction (ADR) and were concurrently
reevaluated as a DIAP episode. In the end, cases from 29 articles
were included in the qualitative and quantitative analysis.
Study Population
Based on the case reports found and a case previously re-
ported by us,11 36 patients with fifty-one 5-ASA–DIAP episodes
were included in the qualitative and quantitative analysis. Each
DIAP episode was considered as a discrete event, and the further
characterization of the study population was based on the hospital-
ization events instead of the patients.
Control Population
To characterize the clinical course of 5-ASA–DIAP as accu-
rately as possible, we established an age- and sex-matched control
AP (CAP) population by using the Hungarian Pancreatic Study
Group (HPSG) electronic registry database. In this database, more
than 1400 cases of patients diagnosed as having AP of various etiol-
ogies were prospectively enrolled over a 6-year period from January
1, 2012, from 17 Hungarian centers. For each 5-ASA–DIAP episode
in the study population, a randomly selected control pair event was
chosen from a patient with the same sex and age. If no event was ac-
cessible in a patient of the same age, age matching was performed in
the range of ±1 year. During the selection process, we excluded all
possible drug-induced cases from the matched CAP population. A
comparison for each variable was made between these 2 matched co-
horts (see Supplemental Table 1, http://links.lww.com/MPA/A716,
which demonstrates etiological diversity of the control age- and
sex-matched population).
In addition, to see whether the epidemiological characteristics
of the population with 5-ASA–DIAP differ from the population
with AP caused by other etiologies, we compared age and sex dis-
tribution to the whole cohort consisting of more than 1400 patients.
Definition of AP
We reevaluated all ADR events documented by the authors
as AP. Each was considered as AP if it met the two-third rule of
epigastric pain and/or pancreatic enzyme levels higher than triple
the normal upper limit and/or morphological pancreatic abnor-
malities seen on imaging according to the International Associ-
ation of Pancreatology/American Pancreatic Association and
HPSG evidence-based guidelines for the management of AP.44,45
FIGURE 1. Detailed procedure of the systematic literature search. Additional records were identified by reading the references of the
articles resulting from the original search and during the process of the online search for the full-text copies. After removing duplicates and
screening, we excluded records that were found not to describe AP cases of 5-ASA–induced etiology. Thirty-six articles were evaluated, and
7 were excluded from the analysis for not describing an episode of AP.
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Pancreatic enzyme level elevationwas considered as higher than tri-
ple the upper normal limit if the authors had stated that there was
biochemical evidence of AP, if the exact enzyme level and upper
normal limit were described, or if the precise extent of elevation
compared with the upper normal limit was provided.
Latency
Latency of 5-ASA–DIAP was defined by the time interval
between the beginning of a drug therapy and the first symptoms
of AP.
Rechallenge
Rechallengewith the offending drug was considered as positive
in the presence or absence of a relapse of AP as long as an ADR
occurred in the form of a pancreatic enzyme level increase and/or
abdominal pain and/or nausea or vomiting.
Severity
To determine the severity of the clinical course of DIAP, we
performed an evaluation using the data provided by the authors
in accordance with the revised Atlanta classification system.46
MildAPwas defined by absence of organ failure, or local or systemic
complications. Moderately severe AP was characterized by transient
organ failure (with symptoms improving within 48 hours) and/or
local (peripancreatic fluid collection, pseudocysts, acute necrotic
collection, and walled-off necrosis) or systemic complications.
Severe AP was characterized by persistent organ failure (not im-
proving in 48 hours) of one or multiple organs.
Causality Assessment
The causal relationship between drug intake and 5-ASA–DIAP
was assessed with the Naranjo algorithm47 to estimate the probability
of ADRs. Each case was evaluated using the questionnaire and was
assigned a value. The cases were thus categorized into the following
groups: any adverse reactionwas categorized as definitewhen scored
≥9, a score of 5 to 8was rated as probable, 1 to 4was considered pos-
sible, and 0 was viewed as a doubtful correlation according to
the algorithm.
Interpretation of the Data
The analysis of the variables studied was conducted with de-
scriptive statistics (mean ± standard error of the mean) and relative
frequency (Fisher exact test and the Mann–Whitney test). A 2-sided
P value of <0.05 was regarded as statistically significant. The
available-case analysis was used for missing data. Statistical anal-
yses were performed using the Statistical Package for the Social
Sciences (SPSS) for Windows version 22.0 (IBM, Armonk, NY).
The established study population of patientswith 5-ASA–DIAP
was created based on case reports. The case reporting system has
some limitations in reporting quality; therefore, statistical conclu-
sions drawn in this study based on this database must be handled
with caution.
Results of the Cohort Analysis
Demographic Data
Of the fifty-one 5-ASA–DIAP cases identified, 60.78%were
female (n = 31) and 39.22%weremale (n = 20). Drug-inducedAP
due to intake of a 5-ASA–derived drug as treatment of IBD oc-
curred at a significantly younger age compared with AP of
other, more common etiologies according to the HPSG registry
(27.31 ± 1.56 years vs 55.98 ± 0.45 years, P < 0.001; Fig. 2B).
In the 5-ASA–DIAP population, 21.57% (n = 11) were pediatric
cases (<18 years of age). There were 70.59% (n = 36) 5-ASA–DIAP
cases that were caused by treatment of ulcerative colitis and
25.49% (n = 13) that resulted from medications taken for Crohn
disease. There were no data in the reporting on the primary condi-
tion in 2 cases.
Acute pancreatitis was described in the literature using mul-
tiple types of 5-ASA–derived drugs: mesalazine (nonconjugated
5-ASA), sulfasalazine (5-ASA and a sulfapyridine moiety joined
by an azo bond), olsalazine (two 5-ASA radicals linked by a diazo
bond), and ethyl-cellulose–coated, time-dependent and resin-
coated, pH-dependent 5-ASA formulations (prolonged-release
preparations for supporting absorption in the distal gastrointesti-
nal tract), the latter 2 available as oral or rectal formulations. In
most cases, AP occurred due to intake of sulfasalazine in
29.41% (n = 15). A therapy with 5-ASA in otherwise unspecified
formulationwas responsible for AP in 23.53% (n = 12). pH-dependent
and time-dependent coated forms resulted in AP in 19.61%
(n = 10) and 13.73% (n = 7), respectively. 5-Aminosalicylic acid
applied as a rectal enema or suppository caused AP in 3.92% of
the cases (n = 2), and olsalazine did so in 1.96% (n = 1). There
were 7.84% (n = 4) AP cases that occurred due to intake of 2 dif-
ferent 5-ASA formulations.
The etiological factors in the CAP cohort were the following:
biliary (31.4% [n = 16]); idiopathic (23.5% [n = 12]); alcohol con-
sumption (19.6% [n = 10]); post–endoscopic retrograde cholan-
giopancreatography (5.9% [n = 3]); anatomical disorders and
dietary noncompliance (both, 3.9% [n = 2]), hypertriglyceridemia,
FIGURE 2. Epidemiological differences between the 5-ASA–DIAP population and the total HPSG cohort with AP caused by other etiologies. A,
Differences of sex distribution showed a female dominance for 5-ASA–DIAP comparedwithmost patients with AP of various etiologies being
male. B, A comparison of the 5-ASA–DIAP population with the total cohort of patients with AP of various etiologies showed a significantly
younger age group affected by 5-ASA–DIAP.
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genetic predisposition, and extraintestinal manifestation of IBD
(all 3, 2% [n = 1]); and multiple, mixed etiologies of the previ-
ously mentioned (5.9% [n = 3]). A summary of the main charac-
teristics of the 5-ASA–DIAP and CAP population is presented
in Figure 3.
Causality Assessment and Evidence Level of Reporting
There was no case found during the literature search with
definite causality (Naranjo score ≥9) between AP and drug admin-
istration (eg, in which IBD is treated with a monotherapy of a
5-ASA–derived drug and all other etiologies of AP were concur-
rently investigated and excluded). In some case reports, there were
no data provided on the exclusion of other etiologies and the possi-
bility of causality between drug intake and AP. There were 55.56%
(n = 20) of the patients who were rechallenged with a 5-ASA–derived
drug (Fig. 4A). Of all DIAP cases, 91.67% (n = 33) were assessed
as probable 5-ASA–induced AP, of which 8.33% received a score
of 8, 38.89% were rated as 7, 5.56% scored 6, and 38.89%
received a 5 using the Naranjo algorithm for estimating the
probability of ADRs. Three articles were evaluated as describing
possible ADRs with a score of 4 (Fig. 4B).
Imaging Alterations and Symptoms
Imaging data in the form of either abdominal ultrasonography
and/or computer tomographywas available in 76.5% (n = 39) of the
5-ASA–DIAP population, of which 64.7% (n = 33) had imaging al-
terations. In the CAP population, 90.2% (n = 46) underwent
transabdominal imaging examinations and 68.6% (n = 35) were di-
agnosed with imaging alterations (Fig. 5A). Acute pancreatitis
caused by this drug type is usually described as manifesting in an
edematous or enlarged pancreas. In the 5-ASA–DIAP population,
a localized or diffuse edema or enlargement of the pancreas was
demonstrated in 54.9% (n = 28), and the pancreas was identified
as normal in 11.8% (n = 6) of the cases. In the CAP group, an
edema or enlargement and normal structure of the pancreas were
detected both in 23.5% of the cases (n = 12). In the 5-ASA–DIAP
population, there were 3 cases of necrotizing pancreas (5.9%),
1 case of peripancreatic inflammation, and 1 case of pseudocyst
formation with effusion.
In the CAP population, imaging characteristics were described
in a more detailed manner; involvement of necrosis in AP and com-
mon bile duct dilatation were both identified in 11.8% of that pop-
ulation (n = 6), fluid collections (peripancreatic, free fluid, or
ascites) in 37.3% (n = 19), and pseudocysts in 5.9% (n = 3).
FIGURE 3. Characterization of the 5-ASA–DIAP and CAP populations. A, Primary reasons for 5-ASA treatment in the study population. B,
Types of 5-ASA–derived drug formulations reported to cause AP in the study population. C, Etiological factors contributing to AP in the
matched-control population. 5-ASA pH, pH-dependent formulation; 5-ASA R, rectally administered formulations; 5-ASA T, time-dependent
formulation; CD, Crohn disease; N/A, not applicable (condition not specified); UC, ulcerative colitis.
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Abdominal pain was present in 90.2% (n = 46) and was
coupled with nausea and/or vomiting in 19.6% (n = 10) of the
5-ASA–DIAPepisodes comparedwith 98% (n = 50) of caseswith
abdominal pain being accompanied by nausea and/or vomiting in
74.5% (n = 38) in the CAP cohort. Pancreatic enzyme level eleva-
tion occurred in the 5-ASA–DIAP population in 80.4% (n = 41) of
the episodes compared with 86.3% (n = 44) in the CAP group. In
45.1% (n = 23) of the 5-ASA–DIAP cases, all 3 diagnostic criteria
were present compared with 58.8% (n = 30) in the CAP population.
A summary of the presence of abdominal pain of pancreatic local-
ization, pancreatic enzyme level elevation, and imaging alterations
as the 3 main diagnostic criteria of AP is presented in Figure 5C.
FIGURE 4. Evidence level of 5-ASA–DIAP case reports. A, The rate of case reports with and without rechallenge with 5-ASA–derived
medication. B, Case reports categorized according to the quantified causal relationship between intake of 5-ASA and AP using the Naranjo
ADR probability scale.
FIGURE 5. Clinical course of 5-ASA–DIAP compared with CAP caused by various etiologies. A, Proportional differences of imaging alterations (if
performed) on admission in the 5-ASA–DIAP and CAP groups. B, Percentage of the severity groups in the 5-ASA–DIAP and CAP populations. A
significant differencewas found between the rates formoderately severe AP groups. C, A comparison of the clinical course of the 5-ASA–DIAP and
CAP populations with regard to the presence of the following diagnostic criteria: P, pain (characteristic epigastric); E, enzyme level elevation
(pancreatic); and I, imaging alteration. D, Significant differences were found by comparing the time interval for symptomatic improvement and
enzyme level normalization (in days) between the 5-ASA–DIAP and CAP groups. Abdominal pain subsided faster, but pancreatic enzyme levels
normalized more slowly in cases of 5-ASA–DIAP.
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Severity and Mortality
In the 5-ASA–DIAP population, drugs caused clinically mild
AP in 88.24% (n = 45) of the cases, a rate that is markedly higher
than that of the CAP group (70.6% [n = 36]). In the 5-ASA–DIAP
group, 4 episodes (7.84%) of severe APwere diagnosed compared
with 3.9% (n = 2) in the CAP population. A significant difference
(P < 0.05), however, was only found between the rates of moder-
ately severe cases in the 5-ASA–DIAP population (3.92% [n = 2])
and the CAP group (25.49% [n = 13]; Fig. 5B). Overall mortality
in the 5-ASA–DIAP population due to complications from clini-
cally severe AP was 3.92% (n = 2, half of the severe cases). No
deaths in the mild and moderately severe groups were registered.
In the CAP population, no lethal episode was found. Interestingly,
5-ASA–DIAP tended to be milder in most of the cases because of
the sparse group of moderately severe cases compared with the
CAP population of other etiologies (Fig. 4).
Resolution of AP
Length of hospitalization was usually not described by the
authors of the studies identified; in 82.4% of the cases, no infor-
mation on this variablewas provided. Consequently, a comparison
was not made because of lack of data. To characterize the timeline
of the clinical course of 5-ASA–DIAP, we collected data on time
intervals of symptomatic improvement and enzyme level normali-
zation. Symptoms improved significantly faster for 5-ASA–DIAP
after discontinuation of the drug compared with the CAP cases
(in 2.5 ± 0.34 vs 3.74 ± 0.42 days, P = 0.018), thus confirming lit-
erature data on rapid symptomatic recovery after dechallenge
(Fig. 5D). However, a less investigated parameter, pancreatic
enzyme level normalization, was found to occur significantly
more slowly in the 5-ASA–DIAP population compared with the
CAP cases (in 6.27 ± 1.53 days vs 3.63 ± 0.61 days, P = 0.008).
Consequently, we cannot conclude a rapid overall resolution of
5-ASA–DIAP. The significant differences in resolution period
could be a consequence of DIAP being potentially an immune-
mediated reaction with a slow overall fall-off of the disease.
Characterization of 5-ASA–DIAP Populuation
Pathomechanism of 5-ASA–DIAP
Of the 29 publications included, the authors suggest an in-
volvement of a hypersensitive reaction in the pathomechanism
of 5-ASA–DIAP in 38.9% (n = 14). Idiosyncrasy is thought to
have a role in 8.3% (n = 3), and one publication suggests a
dose-dependent toxic mechanism. In 62.6% (n = 20), no data on
the pathomechanism are provided (it is either not noted or de-
scribed as unknown). According to the usual opinion found in
the literature data, the mechanism is not dose dependent. This the-
ory is partially supported by the data found because AP developed
in patients with a low (0.8 g/d) and a relatively high (4 g/d) dosage
of 5-ASA–derived drugs. The mean dosage administered was
2.43 ± 0.16 g/d if an average was calculated for all ADRs (evalu-
ated as non-AP and AP). Average dosage taken during AP events
(2.62 ± 0.19 g/d) was compared with average dosage taken during
non-AP adverse events (2.09 ± 0.26 g/d), but the difference was
shown not to be significant (P = 0.149). However, it is important
to note that in some cases, AP occurred under long-term treatment
(latency ≥1 year) with 5-ASA–derived drugs just a few weeks or
months after the dose was increased.32,42 Al-Zayani15 reported on
such a case as well, in which the author presumed a dose-
dependent toxic pathomechanism of 5-ASA–DIAP. The author
doubled the dose of pH-dependent 5-ASA taken by the patient just
3 months before AP occurred after 1 year of constant, symptom-
free treatment with low-dose medication.
Latency
Latency of 5-ASA–DIAP varies between a few days and a
fewweeks according to the literature. However, AP can develop even
after 1 year of therapy with a constantly low dose of 5-ASA–derived
medication.40 After we excluded the data on long-term therapies
(latency≥1 year), the average latency of 5-ASA–DIAPwas found
to be 43.82 ± 10.59 days from the start of the therapy to the onset
of the first AP episode. There were 75% 5-ASA–DIAP episodes
that occurred in less than 153 days, and 25% of them presented
in less than 9 days from the first day of therapy. The interquartile
range was found to be 145 days.
Rechallenge
In all of the identified cases, rechallenege with the 5-ASA–
derived drug was proven as positive. Recurrence of epigastric pain
and/or enzyme level elevation is usually very quick if 5-ASA is
reintroduced. In analyzing the clinical course, no case was found,
in which a rechallenge resulted in more severe ADR compared
with the first. In 3 of the 4 severe AP cases in the 5-ASA–DIAP
population,23,36 a rechallenge was not performed and 2 patients
died in the first episodes. In the fourth case,29 a clinically mild re-
lapse of AP occurred after readministration of the medication. Re-
challenge performed with 5-ASA–derived drugs resulted in mild
DIAP in all cases if ADR was evaluated as a relapse of AP.
DISCUSSION
The established study population with 5-ASA–DIAP was
found significantly younger compared with the population of pa-
tients with AP of other etiologies.
The study confirmed literature data in so far as DIAP caused
by this drug type seems to be milder, with significantly fewer
moderately severe episodes compared with AP caused by more
common etiologies. This can be explained by the usually
self-limited nature of DIAPwith fewer local and systemic compli-
cations. Both severe episodes and mortality occurred at (nonsig-
nificantly) higher rates than expected compared with the CAP
population. These differences in fact may be the result of the poor
overall quality of the case reporting, a higher tendency to report
severe cases of DIAP or underdiagnosis of DIAP cases due to
various challenges.
5-Aminosalicylic acid–DIAP showed a significantly faster
symptomatic improvement after permanent discontinuation of
the offending drug; in parallel, however, a significantly slower enzy-
matic normalization was found compared with the CAP population
of other etiologies. Thus, the literature data on the markedly quick
symptomatic improvement after drug discontinuation were sup-
ported by these findings; however, a slower pancreatic enzyme level
normalization means a longer resolution period of 5-ASA–DIAP in
total compared with the CAP population.
It is important to note that IBD patients are special cases with
regard to the evaluation of onset and presence of abdominal pain
because pain due to this primary condition can easily mask ab-
dominal pain of pancreatic localization as a diagnostic character-
istic of AP.
The latency between the beginning of drug therapy and the
first symptoms of AP was found to be mostly less than 153 days,
a result that partly supports the literature data; however, in several
cases, 5-ASA–DIAP occurred during long-term therapy as well.
In these cases, the dose of the medication was generally increased
just a few weeks or months before the AP episode, suggesting a
possible dose dependency factor in the pathomechanism, which
is usually thought to be a dose-independent hypersensitivity reac-
tion. The exact pathomechanism of 5-ASA–DIAP may thus have
to be further investigated and confirmed.
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If a rechallenge was performed, a rapid relapse usually oc-
curred; however, rechallenge with a 5-ASA–derived drug did
not represent a risk for a more severe AP episode compared with
the first. These findings raise the question: does rechallenge pose
a greater risk under a strict, clinically controlled environment to
ensure the best maintenance therapy during remission for patients
with IBD than a possible recurrence ofmild AP? Interestingly, in a
large cohort analysis,1 the authors concluded that neither mortality
nor severity was affected by recurrence of AP. If we consider re-
challenge as a special type of recurrence of DIAP, our data are
in full accordance with these findings.
No report was found with a highest level of causal corre-
lation, which would represent the strongest evidence of any
link between drug intake and AP. 5-Aminosalicylic acid–
DIAP cases in which all potential etiologies are excluded
and which are positively rechallenged in parallel remain
sparse. The major problem during evaluation of an ADR is
that there is no internationally agreed-upon standard method
for assessing causality between drug intake and the adverse
event. There are a variety of methods, of which any are used
or no causality assessment tool is applied at all. However,
there is a huge need to use a uniform method in attempting
to quantify the causal relationship, not only to be able to esti-
mate the real incidence of DIAP but also to characterize the
clinical course.47
Of course the study has several limitations. First of all, this
study is a cohort analysis based on case report data with limita-
tions in reporting quality. Case reports are often writtenwith insuf-
ficient data, and this may cause imprecisions in our analysis,
which we are aware of. Moreover, we cannot exclude the possibil-
ity of publication bias. Investigators may not publish cases that are
very mild or from the opposite end, which has fatal outcome
in DIAP.
Our data highlight the importance of future studies on DIAP
to understand the baseline characteristics of this disease.
In summary, this study confirms that there are no diagnostic
differences between 5-ASA–DIAP andAPof other etiologies. Symp-
toms improved faster; however, enzyme elevation persists longer in
the case of 5-ASA–DIAP. Less moderate but more severe cases were
found in the 5-ASA–DIAP group; therefore, 5-ASA–DIAP must be
taken as seriously as AP of other etiologies.
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